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Abstract
Dynorphin A 1–17 (Dyn A 1–17) is an endogenous neuropeptide known to act at the kappa opioid
receptor; it has been implicated in a number of neurological disorders, including neuropathic pain,
stress, depression, and Alzheimer’s and Parkinson’s diseases. The investigation of Dyn A 1–17
metabolism at the blood-brain barrier (BBB) is important since the metabolites exhibit unique
biological functions compared to the parent compound. In this work, Dyn A 1–6 is identified as a
metabolite of Dyn A 1–17 in the presence of bovine brain microvessel endhothelial cells
(BBMECs), using LC-MS/MS. The transport of Dyn A 1–6 at the BBB was examined using this
in vitro cell culture model of the BBB. Furthermore, the permeation of the BBB by the low
molecular weight, permeability marker fluorescein was characterized in the presence and absences
of Dyn A 1–6.
1. Introduction
Investigating the transport and metabolism of endogenous substances at the blood brain
barrier (BBB) is important for determining their potential role in neurodegenerative
diseases. In particular, the metabolism and transport of neuropeptides at the BBB can
provide insight into their role in CNS disorders. Dynorphin A 1–17 (Dyn A 1–17) is an
endogenous neuropeptide known to act at the kappa opioid receptor. Upregulation of Dyn A
1–17 synthesis has been implicated in a variety of neurological disorders, including
Alzheimer’s [20], Parkinson’s [11], neuropathic pain [14], stress[12], and depression [17],
and at elevated concentrations, has been shown to be neurotoxic [9, 10, 15]. Once released
into the extracellular space, neuropeptides undergo enzymatic degradation, and therefore,
investigating Dyn A 1–17 metabolism at the blood-brain barrier (BBB) is important since
the metabolites exhibit unique biological functions compared to the parent compound.
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Therefore, it is possible that a metabolite, rather than the parent peptide, may be responsible
for some of the reported neurotoxic effects of dynorphin.
Dyn A 1–6, the N-terminal fragment of Dyn A 1–17, has been identified as a major
metabolite of the parent peptide Dyn A 1–17, by our group and others, in both the central
nervous system (brain and spinal cord) [11, 13, 16] and peripheral tissues (blood and
plasma) [6, 7, 13, 21]. Therefore, this communication describes the initial studies employed
to characterize the BBB permeability of Dyn A 1–6 and the effect of the peptide on cell
monolayer integrity, utilizing the in vitro cell culture model of the BBB developed by Audus
and Borchardt [1]. The bovine brain microvessel endothelial cells (BBMECs) [1] cells
exhibit many of the physical characteristics typical of the BBB such as tight junctions,
decreased pinocytosis, and minimal fenestration. Additionally, the biological aspects of the
blood-brain barrier are simplified considerably enabling the investigation of a compound’s
behavior at the brain endothelium as opposed to the whole brain [8].
The studies described here employed liquid chromatography with tandem mass spectrometry
(LC-MS/MS) to determine the permeation of Dyn A 1–6 across the BBMEC monolayers.
The LC-MS/MS method required minimal sample preparation and no derivatization steps.
Improved limits of detection were achieved using LC-MS/MS in comparison to a previously
described CE-UV method [13]. Additionally fluorescein was employed as a low molecular
weight, membrane-impermeant molecule to probe the effect of Dyn A 1–6 on cell




All dynorphin peptides (Dyn A 1–17, 2–17, 1–13, 1–8, and 1–6) were obtained from
Bachem Biosciences Inc. (King of Prussia, PA, USA). Bradykinin was purchased from
Sigma-Aldrich (St. Louis, MO, USA). Fisher Optima acetonitrile (LC-MS grade) was used
for all mobile phases (Fisher Scientific, Fair Lawn, NJ, USA). Formic acid was purchased
from Acros Organics (Morris Plains, NJ, USA) at 99.9% purity. All aqueous mobile phases
were made from 18 MΩ deionized (D.I.) water from a benchtop Milli-Q Synthesis A10
Water Purification System (Millipore, Billerica, MS, USA) and filtered with 0.2 µm Magna
nylon filters from Osmonics (Minnetonka, MN, USA). Minimum essential medium (MEM)
and Ham’s F12 were purchased from Life Technologies, Invitrogen Corporation (Carlsbad,
CA, USA). All other reagents were purchased from Sigma Aldrich.
2.2. Isolation and maintenance of bovine brain microvessel endothelial primary cultures
Microvessel endothelial cells were isolated from the cortical grey matter of bovine brains by
enzymatic digestion and centrifugation as described by Audus and Borchardt in 1986 [1]. A
short description of the isolation procedure is included in the Supplemental Information.
2.3. Analysis of BBMEC integrity and Dyn A 1–6 transport at the cell monolayer
At the beginning of each transport study, the polycarbonate membranes were removed and
mounted in Side-by-Side™ diffusion chambers (Crown Glass Inc., Somerville, NJ, USA).
Prior to studies, the diffusion chambers were silanized with Sigmacote (Sigma-Aldrich) to
prevent peptide adsorption to the chamber walls during the study. On the day of the study,
chambers were pre-warmed (37 °C) and rinsed three times with mPBSA. The chamber
temperature was maintained for the duration of the study by external circulating water baths
(at either 37 °C or 4 °C, depending on the experiment) and each chamber was stirred
constantly at 600 rpm by Teflon-coated magnetic stir bars driven by an external console.
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The donor side was then spiked with Dyn A 1–6, and 60 µL aliquots were removed from the
receiver side at various timepoints and replaced with an equal volume of mPBSA to prevent
changes in volume that could affect flux. Studies typically lasted 2–4 h. All samples were
collected into autosampler vials containing H2O with formic acid. Mass balance samples
were collected from the receiver chamber at the start and finish of each experiment.
Quantitation was performed via LC-MS/MS. All Liquid chromatography-tandem mass
spectrometry instrumentation and experimental details are described in the supplemental
information.
Upon completion of the transport study, fluorescein was added to the apical side of the
monolayer and utilized to test the monolayer integrity. Immediately, a 100 µL aliquot was
removed from the donor chamber and placed in a 96-well plate. Additional 100 µL aliquots
were taken from the receiver chamber (t = 10, 20, 30, and 60 min), and a final sample was
taken from the donor chamber after 60 min as well. Fluorescein samples were placed
directly into a 96-well plate and analyzed using a fluorescence microplate spectrophotometer
(Molecular Devices, Sunnydale, CA, USA) at excitation and emission wavelengths of 490
and 520 nm, respectively.
For studies determining the permeation of fluorescein without Dyn A 1–6 pretreatment,
chambers were filled with the modified medium (mPBSA), and the cells were allowed to
equilibrate for 5 min. After the equilibration period, fluorescein was added to the apical side
and samples were removed from the donor chamber as described above.
All permeation values determined using the following equation: Papp = (ΔQ/Δt)/ A × C0,
where ΔQ/Δt is the linear appearance of fluorescein in the receiver chamber, A is the cross-
sectional area of the cell monolayer (0.636 cm2), and C0 is the initial concentration in the
donor chamber at t = 0.
3. Results
In this work and that of others, Dyn A 1–6 has been identified as a major metabolite of the
parent peptide Dyn A 1–17 in both the central nervous system (brain and spinal cord) [11,
13, 16] and peripheral tissues (blood and plasma) [6, 7, 13, 21]. Dyn A 1–6 was also
identified as a metabolite in the presence of bovine brain microvessel endothelial cells
(BBMEC) (supplemental information- Figure S1). For this reason, the BBB permeability of
Dyn A 1–6 was investigated, using BBMECs grown on polycarbonate membranes and
mounted in Side-by-Side™ diffusion chambers. Fluorescein was utilized as a low
permeability control following all experiments to examine monolayer integrity.
Both the directional and temperature dependence of Dyn A 1–6 permeation were determined
by replacing 20 µL of mPBSA with Dyn A 1–6 stock solution resulting in a peptide
concentration of 18.6 µM in the donor compartment. The apparent permeability coefficient
of Dyn A 1–6 was calculated to be Papp = 6.59 × 10−5 cm/s (±1.74 × 10−5 n = 4), in the
apical to basolateral direction, and Papp = 6.43 × 10−5 cm/s (±1.61 × 10−5 n = 4), in the
basolateral to apical direction. There was no difference in the permeability based on
direction (Fig. 1A). A decrease in permeation was observed at 4 °C, Papp = 1.11 × 10−5 cm/s
(±2.90 × 10−6, n = 4, p < 0.005), suggestive of a carrier-mediated transport system (Fig. 1A).
Fluorescein was utilized as a low molecular weight permeability marker and control
following the end of each experiment. Values for fluorescein permeation are presented in
Fig. 1B.
Interestingly the permeation values for fluorescein were increased following Dyn A 1–6
exposure at 37 °C in comparison to those at 4 °C. Thus control experiments were performed
to confirm the permeation value for fluorescein without Dyn A 1–6 preincubation.
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Fluorescein permeation was calculated to be 3.42 × 10−5 cm/s (± 2.90 × 10−5 n = 4), and this
value agrees well with previous literature reports [18, 19], indicating that the cell
monolayers were confluent and intact on the polycarbonate membranes.
The effect of Dyn A 1–6 preincubation on fluorescein permeation was further investigated
by incubating mounted monolayers for 2 h in mPBSA at 37 °C. Following the 2-h
incubation, 0, 20, and 100 µL of mPBSA were removed and replaced with Dyn A 1–6
resulting in final concentrations in the chamber of 0, 18.6, and 46.6 µM. The fluorescein
permeability increased in a linear fashion with increasing exposure to Dyn A 1–6, R2 =
0.9995. The permeation values for Dyn A 1–6 in the apical-to-basolateral and basolateral-to-
apical directions fall along this line, as shown by the open square and open diamond data
points in Fig. 2, suggesting that this peptide is responsible for increasing BBB permeability.
A similar phenomenon was observed by Thompson and Audus with the opioid peptide
leucine enkephalin [18, 19], and the reported values for fluorescein permeation both with
and without leucine enkephalin pretreatment are also plotted in Fig. 2 for comparison.
4. Discussion
It has been reported that leucine enkephalin can increase the permeation of low molecular
weight, membrane-impermeant molecules such as sucrose and fluorescein in a
concentration-, energy-, and temperature-dependent manner [2, 18, 19]. Metabolites of Leu-
enkephalin did not exhibit this effect, nor did metabolically stable analogs. It is also well
known that there exists a saturable peptide transport system for small, N-tyrosinated
peptides at the blood-brain barrier [3–5], and that this system is responsible for the brain-to-
blood efflux of the small opioid peptide leucine enkephalin. Thompson and Audus found
that non-opioid peptides capable of utilizing this transport system did not alter BBB
permeability to fluorescein or sucrose, suggesting that binding this efflux system is not
responsible for BBB opening [18, 19]. However, the use of naloxone, a mu- and delta-opioid
antagonist, was shown to attenuate the increased transport caused by Leu-enkephalin.
This result indicates that opioid receptor activity (delta or mu) may play a role in the ability
of these peptides to open the BBB. Dyn A 1–17 acts preferentially at the kappa-opioid
receptor, while Dyn A 1–6 shares affinity for the kappa, mu, and delta receptors. Dyn A 1–6
has not been found to be neurotoxic, but it could be responsible for opening the blood-brain
barrier, allowing increased transport of the parent peptide in addition to other harmful
substances. Further studies are underway to determine the mechanism responsible for the
Dyn A 1–6-induced increase in BBB permeability.
4. Conclusions
This paper describes the application of the BBMEC culture model to the permeation of Dyn
A 1–6, a metabolite of the neuropeptide Dyn A 1–17, at the blood brain barrier. LC-MS/MS
was utilized to quantify Dyn A 1–6 in order to determine the bi-directional permeation of the
peptide the BBB. Dyn A 1–6 transport was decreased at 4 °C, indicating an energy- (ATP)
driven transport mechanism is likely responsible. The metabolite was also found to increase
the permeability of the BBB to a low molecular weight, low permeability control substance,
fluorescein. Such effects suggest a role of this dynorphin metabolite in the opening of the
BBB, specifically to low molecular weight compounds, including the peptide itself.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Dynorphin A 1–6 is identified as a metabolite of Dynorphin A 1–17 in the
presence of bovine brain microvessel endothelial cells (BBMECs).
• The blood brain barrier (BBB) permeability of the neuropeptide Dyn A 1–6 is
investigated using the BBMEC culture model of the BBB.
• The directional and temperature dependent permeation of Dyn A 1–6 is
evaluated.
• Dyn A 1–6 pretreatment is found to induce an opening of the BBB, increasing
the permeation of fluorescein, a low molecular weight, low permeability control
substance.
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(A) Bi-directional apparent permeability coefficients of Dyn A 1–6 (n =4 in each direction)
and the temperature dependence of the apical-to-basolateral transport of Dyn A 1–6 (n = 4 at
each temperature) p < 0.005. (B) Effect of pretreatment with 18.6 µM Dyn A 1–6 on the
BBB permeability of the low molecular weight, low permeation marker, fluorescein (10
µM), n = 4.
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Effect of pretreatment with varying Dyn A 1–6 concentrations (solid diamonds) on the BBB
permeation of the low molecular weight, low permeability marker fluorescein (10 µM).
Fluorescein permeation without Dyn A 1–6 incubation (open diamonds), fluorescein
permeation following 240-min Dyn A 1–6 pretreatment A to B (open triangles) and B to A
(open squares), and fluorescein permeation following 120-min Dyn A 1–6 pretreatment at 4
°C (open circles). Also shown are literature values for the permeation of fluorescein alone
(dash) and following pretreatment with leucine enkephalin (plus sign).
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